JP2009506018A - テトラヒドロキノリノン類及び代謝型グルタミン酸受容体のモジュレータとしてのその使用 - Google Patents

テトラヒドロキノリノン類及び代謝型グルタミン酸受容体のモジュレータとしてのその使用 Download PDF

Info

Publication number
JP2009506018A
JP2009506018A JP2008527513A JP2008527513A JP2009506018A JP 2009506018 A JP2009506018 A JP 2009506018A JP 2008527513 A JP2008527513 A JP 2008527513A JP 2008527513 A JP2008527513 A JP 2008527513A JP 2009506018 A JP2009506018 A JP 2009506018A
Authority
JP
Japan
Prior art keywords
quinolin
dihydro
dimethyl
ylethynyl
phenylethynyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008527513A
Other languages
English (en)
Japanese (ja)
Inventor
パーソンズ・クリストファー・グラハム・ラファエル
イルゲンソンズ・アイガルス
ヤウンゼメ・イエヴァ
カルヴィニシュ・イヴァルス
ヘンリヒ・マルクス
ヴァネイェヴス・マクシムス
ヴァイル・タンヤ
カウス・ヴァラーヤンス
ダニュシュ・ヴォイチェフ
ヤッツケ・クラウディア
Original Assignee
メルツ・ファルマ・ゲゼルシヤフト・ミト・ベシュレンクテル・ハフツング・ウント・コンパニー・コマンデイトゲゼルシヤフト・アウフ・アクティーン
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メルツ・ファルマ・ゲゼルシヤフト・ミト・ベシュレンクテル・ハフツング・ウント・コンパニー・コマンデイトゲゼルシヤフト・アウフ・アクティーン filed Critical メルツ・ファルマ・ゲゼルシヤフト・ミト・ベシュレンクテル・ハフツング・ウント・コンパニー・コマンデイトゲゼルシヤフト・アウフ・アクティーン
Publication of JP2009506018A publication Critical patent/JP2009506018A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2008527513A 2005-08-24 2006-08-24 テトラヒドロキノリノン類及び代謝型グルタミン酸受容体のモジュレータとしてのその使用 Pending JP2009506018A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/GB2005/003285 WO2007023242A1 (fr) 2005-08-24 2005-08-24 Tétrahydroquinolinones et leur usage en tant que modulateurs des récepteurs de glutamate métabotropiques
PCT/GB2006/003170 WO2007023290A1 (fr) 2005-08-24 2006-08-24 Tétrahydroquinolinones et leur utilisation comme modulateurs de récepteurs métabotropique de glutamate

Publications (1)

Publication Number Publication Date
JP2009506018A true JP2009506018A (ja) 2009-02-12

Family

ID=36273537

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008527513A Pending JP2009506018A (ja) 2005-08-24 2006-08-24 テトラヒドロキノリノン類及び代謝型グルタミン酸受容体のモジュレータとしてのその使用

Country Status (15)

Country Link
EP (1) EP1931635A1 (fr)
JP (1) JP2009506018A (fr)
KR (1) KR20080031972A (fr)
CN (1) CN101223142A (fr)
AR (1) AR056044A1 (fr)
AU (1) AU2006283359B2 (fr)
BR (1) BRPI0615059A2 (fr)
CA (1) CA2610873C (fr)
EA (1) EA200800660A1 (fr)
IL (1) IL189617A (fr)
MX (1) MX2008001871A (fr)
NO (1) NO20081428L (fr)
TW (1) TWI329635B (fr)
WO (2) WO2007023242A1 (fr)
ZA (1) ZA200710668B (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013514325A (ja) * 2009-12-18 2013-04-25 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ｍＧｌｕＲ５受容体のアロステリック調節因子としての二環式チアゾール
JP2013514327A (ja) * 2009-12-18 2013-04-25 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ｍＧｌｕＲ５受容体のアロステリック調節因子としての二環式チアゾール
JP2022553323A (ja) * 2019-10-21 2022-12-22 エスケー バイオファーマスティカルズ カンパニー リミテッド 認知障害の予防、軽減又は治療、又は認知機能の改善のためのイミダゾピリミジン又はイミダゾトリアジン化合物の使用

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
US8772301B2 (en) 2009-12-18 2014-07-08 Sunovion Pharmaceuticals, Inc. Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
JP2013518085A (ja) 2010-02-01 2013-05-20 ノバルティス アーゲー ＣＲＦ−１受容体アンタゴニストとしてのピラゾロ［５，１ｂ］オキサゾール誘導体
JP5748777B2 (ja) 2010-02-02 2015-07-15 ノバルティス アーゲー Ｃｒｆ受容体アンタゴニストとしてのシクロヘキシルアミド誘導体
AR083475A1 (es) 2010-10-18 2013-02-27 Merz Pharma Gmbh & Co Kgaa Moduladores de receptores de glutamato metabotropicos
WO2012139876A1 (fr) 2011-04-14 2012-10-18 Merz Pharma Gmbh & Co. Kgaa Formulations entériques de modulateurs de récepteur de glutamate métabotropique
WO2012172093A1 (fr) * 2011-06-17 2012-12-20 Merz Pharma Gmbh & Co. Kgaa Dérivé de dihydroindolizine à titre de modulateurs des récepteurs métabotropes de glutamate
WO2013050527A1 (fr) 2011-10-05 2013-04-11 H. Lundbeck A/S Dérivés de quinazoline en tant qu'inhibiteurs de l'enzyme pde10a
EP2650284A1 (fr) * 2012-04-10 2013-10-16 Merz Pharma GmbH & Co. KGaA Dérivés hétérocycliques comme modulateurs de récepteurs du glutamate métabotropique
KR101418078B1 (ko) * 2013-01-23 2014-07-10 한국과학기술연구원 ｍＧｌｕＲ5 길항제로서의 2-(치환된에티닐)퀴놀린 유도체
JP6744218B2 (ja) 2013-11-15 2020-08-19 ザ ウィスター インスティテュート オブ アナトミー アンド バイオロジー Ｅｂｎａ１阻害剤およびそれらの使用方法
KR101579496B1 (ko) * 2014-07-03 2015-12-23 한국과학기술연구원 ｍＧlｕＲ5의 표식용 방사성 조성물
WO2016154527A1 (fr) * 2015-03-26 2016-09-29 Merck Sharp & Dohme Corp. Dérivés de quinolizine substitués par un phosphate utiles en tant qu'inhibiteurs de l'intégrase du vih
BR112017024481B1 (pt) 2015-05-14 2020-11-17 The Wistar Institute Of Anatomy And Biology composto inibidor de ebna1, composição farmacêutica compreendendo dito composto e usos terapêuticos do mesmo
PL3303330T3 (pl) 2015-06-03 2019-10-31 Bristol Myers Squibb Co Agoniści 4 - hydroksy - 3 - ( heteroarylo ) pirydyno - 2 - onowi receptora apj do stosowania w leczeniu zaburzeń sercowo-naczyniowych
EP3459939A1 (fr) * 2017-09-26 2019-03-27 Pragma Therapeutics Nouveaux composés hétérocycliques comme modulateurs de mglur7
TW201946919A (zh) 2018-05-17 2019-12-16 威斯塔研究所 Ebna1抑制劑晶形、其製備方法及其使用方法
CA3155013A1 (fr) * 2019-10-21 2021-04-29 Ki Ho Lee Utilisation de compose d'imidazopyrimidine ou d'imidazotriazine pour la prevention, le soulagement ou le traitement d'un trouble du developpement

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004510764A (ja) * 2000-10-02 2004-04-08 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 代謝共役型グルタミン酸受容体拮抗剤
JP4712027B2 (ja) * 2004-02-27 2011-06-29 メルツ・ファルマ・ゲゼルシヤフト・ミト・ベシュレンクテル・ハフツング・ウント・コンパニー・コマンデイトゲゼルシヤフト・アウフ・アクティーン テトラヒドロキノリノン類及び代謝型グルタミン酸受容体のアンタゴニストとしてのその使用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004510764A (ja) * 2000-10-02 2004-04-08 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 代謝共役型グルタミン酸受容体拮抗剤
JP4712027B2 (ja) * 2004-02-27 2011-06-29 メルツ・ファルマ・ゲゼルシヤフト・ミト・ベシュレンクテル・ハフツング・ウント・コンパニー・コマンデイトゲゼルシヤフト・アウフ・アクティーン テトラヒドロキノリノン類及び代謝型グルタミン酸受容体のアンタゴニストとしてのその使用

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013514325A (ja) * 2009-12-18 2013-04-25 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ｍＧｌｕＲ５受容体のアロステリック調節因子としての二環式チアゾール
JP2013514327A (ja) * 2009-12-18 2013-04-25 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ｍＧｌｕＲ５受容体のアロステリック調節因子としての二環式チアゾール
JP2022553323A (ja) * 2019-10-21 2022-12-22 エスケー バイオファーマスティカルズ カンパニー リミテッド 認知障害の予防、軽減又は治療、又は認知機能の改善のためのイミダゾピリミジン又はイミダゾトリアジン化合物の使用
JP7504203B2 (ja) 2019-10-21 2024-06-21 エスケー バイオファーマスティカルズ カンパニー リミテッド 認知障害の予防、軽減又は治療、又は認知機能の改善のためのイミダゾピリミジン又はイミダゾトリアジン化合物の使用

Also Published As

Publication number Publication date
IL189617A0 (en) 2008-06-05
AU2006283359B2 (en) 2010-05-27
AR056044A1 (es) 2007-09-12
IL189617A (en) 2012-08-30
ZA200710668B (en) 2009-08-26
WO2007023290A1 (fr) 2007-03-01
CN101223142A (zh) 2008-07-16
EA200800660A1 (ru) 2008-06-30
BRPI0615059A2 (pt) 2011-04-26
CA2610873A1 (fr) 2007-03-01
TWI329635B (en) 2010-09-01
KR20080031972A (ko) 2008-04-11
CA2610873C (fr) 2010-08-03
MX2008001871A (es) 2008-04-09
NO20081428L (no) 2008-03-18
TW200728283A (en) 2007-08-01
AU2006283359A1 (en) 2007-03-01
WO2007023242A1 (fr) 2007-03-01
EP1931635A1 (fr) 2008-06-18

Similar Documents

Publication Publication Date Title
JP2009506018A (ja) テトラヒドロキノリノン類及び代謝型グルタミン酸受容体のモジュレータとしてのその使用
JP4712027B2 (ja) テトラヒドロキノリノン類及び代謝型グルタミン酸受容体のアンタゴニストとしてのその使用
US20080032998A1 (en) Pyrazolopyrimidines, a process for their preparation and their use as medicine
JP2013501013A (ja) 代謝調節型グルタミン酸受容体モジュレーター
AU2014204831C1 (en) Benzylideneguanidine derivatives and therapeutic use for the treatment of protein misfolding diseases
JP2011510943A (ja) ピラゾロピリミジン、薬剤としてのそれらの製造法ならびにそれらの使用法
EA016969B1 (ru) 1,3-двузамещенные-4-фенил-1н-пиридин-2-оны
US20070299113A1 (en) Metabotropic glutamate receptor modulators
JP2021519316A (ja) Ｔｌｒ２シグナル伝達の調節剤としての化合物
JP2008515867A (ja) Ｃｎｓ疾患を治療するための、新規環状及び非環状プロペノン類
US7550482B2 (en) Tetrahydroquinolones and their use as modulators of metabotropic glutamate receptors
EP1943247A1 (fr) Tetrahydroquinolinones et leur utilisation en tant que modulateurs des recepteurs metabotropes du glutamate
US20060004001A1 (en) Tetrahydroquinolones and their use as modulators of metabotropic glutamate receptors
WO2012152854A1 (fr) Modulateurs de récepteur de glutamate métabotropique
HK1120260A (en) Tetrahydroquinolinones and their use as modulators of metabotropic glutamate receptors
WO2008035049A1 (fr) Adamantanyl-(cyclopropyl)-cétones utilisées en tant que modulateurs du récepteur métabotropique du glutamate
US20060199978A1 (en) Compounds having serotonin 5-ht17 receptor antagonist activity and muscarinic m4 receptor agonist activity and their use in the treatment of psychotic disorders
TW201309691A (zh) 促代謝性麩胺酸受體調節劑
MXPA06009564A (en) Tetrahydroquinolinones and their use as antagonists of metabotropic glutamate receptors
TW201307301A (zh) 趨代謝性麩胺酸受體調節劑

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20100527

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110823

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20111121

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120207